Home Healthcare Pharmaceuticals Atherosclerosis Market

Atherosclerosis Market Size, Share & Trends Analysis Report By Drug Class (Statins, PCSK9 Inhibitors, Bempedoic-acid & ACL inhibitors, Antiplatelet Agents, Omega-3 Fatty-acid Derivatives, RNA-based Therapies (ASO & siRNA), Other Drugs), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 13, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Atherosclerosis Market, By Drug Class 2025-2034 (USD MILLION/ Units)
    1. Statins
    2. PCSK9 Inhibitors
    3. Bempedoic-acid & ACL inhibitors
    4. Antiplatelet Agents
    5. Omega-3 Fatty-acid Derivatives
    6. RNA-based Therapies (ASO & siRNA)
    7. Other Drugs
  2. Atherosclerosis Market, By Distribution Channel 2025-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Online Pharmacies
  3. Regional Atherosclerosis Market
    1. North America
      1. North America Atherosclerosis Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
      2. North America Atherosclerosis Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      3. U.S.
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      4. Canada
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
    2. Europe
      1. Europe Atherosclerosis Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
      2. Europe Atherosclerosis Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      3. U.K.
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      4. Germany
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      5. France
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      6. Spain
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      7. Italy
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      8. Russia
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      9. Nordic
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      10. Benelux
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      11. Rest of Europe
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
    3. APAC
      1. APAC Atherosclerosis Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
      2. APAC Atherosclerosis Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      3. China
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      4. Korea
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      5. Japan
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      6. India
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      7. Australia
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      8. Taiwan
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      9. South East Asia
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      10. Rest of Asia-Pacific
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Atherosclerosis Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
      2. Middle East and Africa Atherosclerosis Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      3. UAE
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      4. Turkey
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      5. Saudi Arabia
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      6. South Africa
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      7. Egypt
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      8. Nigeria
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      9. Rest of MEA
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
    5. LATAM
      1. LATAM Atherosclerosis Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
      2. LATAM Atherosclerosis Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      3. Brazil
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      4. Mexico
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      5. Argentina
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      6. Chile
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      7. Colombia
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
      8. Rest of LATAM
        1. Statins
        2. PCSK9 Inhibitors
        3. Bempedoic-acid & ACL inhibitors
        4. Antiplatelet Agents
        5. Omega-3 Fatty-acid Derivatives
        6. RNA-based Therapies (ASO & siRNA)
        7. Other Drugs
        8. Hospital Pharmacies
        9. Drug Stores & Retail Pharmacies
        10. Online Pharmacies
Report Details
−
Trusted by Industry Leaders
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com
custom reports
Need a Tailored Report?
80% of our existing clients ask for tailored reports.
Request Customization

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.